Match!
Kenneth Fernald
Erasmus University Rotterdam
7Publications
3H-index
28Citations
Publications 7
Newest
#1Kenneth Fernald (VU: VU University Amsterdam)H-Index: 3
#2Nadine M Janssen (VU: VU University Amsterdam)
Last.Eric Claassen (VU: VU University Amsterdam)H-Index: 34
view all 0 authors...
Biotechnology ventures highly depend on venture capital during early stages. Therefore, insights into investment priorities of venture capitalists can be valuable for bioentrepreneurs. This study presents a systematic prioritization analysis of venture capitalists’ investment priorities in terms of biotechnologies and therapeutic areas, as well as associated investment barriers. By means of 21 qualitative interviews and 81 quantitative questionnaires with venture capitalists, the paper shows tha...
#1Kenneth Fernald (EUR: Erasmus University Rotterdam)H-Index: 3
#2Enrico Pennings (EUR: Erasmus University Rotterdam)H-Index: 19
Last.Eric ClaassenH-Index: 34
view all 5 authors...
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innovation activities of Big Pharma firms. The study indicates a rising interest of Big Pharma in acquisitions of and alliances with biotechnology companies. Unfortunately, this increased interest is not reflected in the number of new drugs generated by Big Pharma. We find that acquisitions of biotech com...
#1Kenneth FernaldH-Index: 3
Last.H.J.H.M. ClaassenH-Index: 1
view all 5 authors...
textabstractIn the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innovation activities of Big Pharma firms. The study indicates a rising interest of Big Pharma in acquisitions of and alliances with biotechnology companies. Unfortunately, this increased interest is not reflected in the number of new drugs generated by Big Pharma. We find that acquisitions of...
#1Kenneth Fernald (EUR: Erasmus University Rotterdam)H-Index: 3
#2Enrico PenningsH-Index: 19
Last.Eric ClaassenH-Index: 34
view all 3 authors...
The management and exploitation of biotechnological product innovation have proven to be more difficult than initially expected because the number of currently marketed biotechnological products is far from sufficient to counter deficits in pharmaceutical innovation. This study provides insight into the role of governance structures in interfirm cooperation and their effects on biotechnological product innovation and company success. Most of the existing literature regarding alliances and merger...
#1Kenneth Fernald (EUR: Erasmus University Rotterdam)H-Index: 3
#2Ruud HoebenH-Index: 1
Last.Eric ClaassenH-Index: 34
view all 3 authors...
Venture capitalists (VCs) aim at trade sales as a preferred exit-strategy for biotechnology companies they invest in. Therefore, VCs pay close attention to the wishes of larger (bio)pharmaceutical acquirers. In this paper we explore VCs’ behavior and strategies by analyzing the technology fields and therapeutic areas in which they are invested most and which yield the highest returns by means of trade sales. The data show that VCs are by far most invested in oncology and this is also an area i...
#1Tamar Weenen (EUR: Erasmus University Rotterdam)H-Index: 7
#2Kenneth Fernald (VU: VU University Amsterdam)H-Index: 3
Last.Eric Claassen (VU: VU University Amsterdam)H-Index: 34
view all 5 authors...
This chapter focuses on the current and possible future development scenarios for the medical nutrition industry. It starts off by exploring the definitions and characteristics of the pharmanutrition industries in the European health and life science sector. By taking conventional foods at one end of the spectrum, and pharmaceutical products at the other, the pharmanutrition industry can be split further into two categories falling within this spectrum: functional foods and medical nutrition. Se...
#1Kenneth FernaldH-Index: 3
#2Tamar WeenenH-Index: 7
Last.Eric ClaassenH-Index: 34
view all 4 authors...
During the past two decades the biopharmaceutical industry has been facing an innovation deficit, characterized by increasing research & development costs and stagnant productivity. From its inception, biotechnology has been expected to counter this deficit by its revolutionary science-based approach to drug discovery. For this study we gathered patent and product data related to the technological development of the first two biotechnologies: recombinant DNA technology and monoclonal antibody te...
1